Globrands Ltd. (TLV:GLRS)

Intra-Cellular Therapies Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 5, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	665	577	521	468	546	457
Market Cap Growth	36.70%	10.81%	11.32%	-14.34%	19.43%	7.45%
Enterprise Value	902	780	724	654	697	563
Last Close Price	538.30	450.62	366.56	291.54	302.34	222.58
PE Ratio	9.36	7.79	8.76	6.66	7.51	6.34
PS Ratio	0.88	0.77	0.78	0.79	0.99	0.88
PB Ratio	8.61	9.42	10.90	8.42	9.82	8.82
P/TBV Ratio	7.92	8.70	11.03	8.52	9.82	8.82
P/FCF Ratio	-	63.64	31.57	-	7.22	7.76
P/OCF Ratio	-	22.00	15.27	-	6.55	7.20
EV/Sales Ratio	1.20	1.03	1.09	1.10	1.27	1.08
EV/EBITDA Ratio	7.94	7.39	8.22	6.42	6.64	5.47
EV/EBIT Ratio	9.59	8.19	9.05	6.89	7.10	5.81
EV/FCF Ratio	-47.71	86.01	43.87	-	9.21	9.56
Debt / Equity Ratio	3.39	6.17	6.68	4.67	2.14	2.30
Debt / EBITDA Ratio	2.30	3.29	3.35	2.41	1.09	1.11
Debt / FCF Ratio	-	41.71	19.33	-	1.58	2.02
Asset Turnover	1.68	1.41	1.44	1.71	2.02	2.00
Inventory Turnover	2.77	2.01	2.04	2.32	2.90	2.94
Quick Ratio	0.48	0.40	0.41	0.42	0.49	0.46
Current Ratio	1.07	1.02	1.04	1.12	1.17	1.14
Return on Equity (ROE)	94.36%	126.03%	103.31%	124.04%	135.40%	145.82%
Return on Assets (ROA)	13.16%	11.13%	10.85%	17.04%	22.60%	23.25%
Return on Capital (ROIC)	20.29%	14.77%	14.66%	24.21%	35.47%	37.27%
Return on Capital Employed (ROCE)	78.00%	89.50%	78.70%	90.20%	128.90%	131.00%
Earnings Yield	10.98%	12.84%	11.42%	15.02%	13.32%	15.78%
FCF Yield	-2.84%	1.57%	3.17%	-11.90%	13.85%	12.88%
Dividend Yield	8.50%	-	12.65%	15.91%	16.95%	33.63%
Payout Ratio	78.02%	76.92%	104.27%	78.27%	94.86%	117.78%
Buyback Yield / Dilution	-0.84%	-1.10%	-1.84%	-	-2.12%	-2.33%
Total Shareholder Return	7.36%	-1.10%	10.81%	15.91%	14.83%	31.30%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.